Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: Relationship with prognosis Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010
Serum levels of interleukin 8 and plasma levels of osteopontin in patients with non-small cell lung cancer during chemotherapy Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011
Prognostic value of il-6 and TNF-alfa serum concentration in advanced non-small lung cancer patients Source: Eur Respir J 2003; 22: Suppl. 45, 251s Year: 2003
Matrix metalloproteinase-9 (MMP-9) elevated in serum, but not in bronchial lavage in lung cancer patients Source: Eur Respir J 2005; 26: Suppl. 49, 328s Year: 2005
The value of CD44 and MMP-2 expression in non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 77s Year: 2004
Increased serum levels of IL-18 are associated with lower survival and bone metastasis in non-small-cell lung cancer Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology Year: 2008
Serum C-reactive protein and procalcitonin levels in non-small cell lung cancer patients Source: Annual Congress 2012 - Instructive clinical aspects of thoracic oncology Year: 2012
Serum levels of STR-3 and TIMP-2 in lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 230s Year: 2002
Importance of clusterin expression at tissue level for the prognosis of non-small cells lung cancer Source: Annual Congress 2009 - Lung cancer biology Year: 2009
The effect of matrix metalloproteinase-9 and vascular endothelial growth factor expression on survival of non-small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 324s Year: 2005
Association of genetic polymorphisms of matrix metalloproteinase (MMP)14 to the susceptibility of non-small cell lung cancer Source: Annual Congress 2011 - Biomarkers and other new methods for lung cancer Year: 2011
Serum level of GFBP-1 and IGFBP-6 in patients with non-small cell lung cancer (NSCLC) during chemotherapy Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009
Plasma leptin levels in nonsmall cell lung carcinoma (NSCLC) patients at the time of the diagnosis Source: Eur Respir J 2001; 18: Suppl. 33, 65s Year: 2001
Evaluation of IL-6 level in serum and bronchoalveolar lavage fluid of patients with non-small cell lung cancer (NSCLC) Source: Annual Congress 2011 - Biomarkers and other new methods for lung cancer Year: 2011
Elevated endogenous thrombin potential in patients with lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 199s Year: 2003
Serum level of IGF-I and IGF-II in patients with non-small cell lung cancer (NSCLC) during chemotherapy Source: Eur Respir J 2004; 24: Suppl. 48, 82s Year: 2004
Serum hepcidin and iron are associated with non-small cell lung cancer stage Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016
Serum level of interleukin-6 as a prognostic factor in advanced nonsmall-cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 250s Year: 2003
Increased concentration of matrix metalloproteinase-9 in serum of COPD patients Source: Eur Respir J 2005; 26: Suppl. 49, 54s Year: 2005
Tissue inhibitors of metalloproteinase-2 C-303T and G-418C genetic polymorphisms are associated with an increased risk of non-small cell lung cancer in Taiwan Source: Annual Congress 2008 - Biology in thoracic tumours Year: 2008